Graam SRL
Graam reported total assets of 252,885 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Graam shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +120 % Total assets +495 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Graam's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 31 Jul 2025
- Year ended 31 Dec 2023filed on 19 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
Graam's financial analysis
- Solvency26.8%sector median: 48.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Graam
Graam's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0781.463.276
- VAT number
- BE0781463276
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 01 Feb 2022
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Activities of blood collection centres, blood banks, sperm banks, transplant organ banks and similar establishments (NACE 86992)
Graam (SRL) has been based in Ixelles since 2022, active in: activities of blood collection centres, blood banks, sperm banks, transplant organ banks and similar establishments. For 2025, it reports a net profit of 56,479 € and equity of 67,784 €; its revenue is not published. Its solvency stands at 26.8%, below the median of its sector (48.0%).
Companies similar to Graam
Companies in the same business, of comparable size and area, outside its group.
- RPO NucleoGenesis Manufacture of basic pharmaceutical products Ghent · balance sheet 107,514 €
- SmileLab Manufacture of medical and dental instruments and supplies Soignies · balance sheet 515,809 €
- Laboratoire GILLES Thomas Manufacture of medical and dental instruments and supplies Stavelot · balance sheet 161,801 €
- Cerdak Manufacture of pharmaceutical preparations Lanaken · balance sheet 103,436 €
- DR. PATRICK SIMONS, huisarts Other human health activities n.e.c. Halle · balance sheet €1.16m
- Cell-Cell BIO Research and experimental development on natural sciences and engineering Ghent · balance sheet 990,571 €
- Estrella Clinical Research Manufacture of basic pharmaceutical products Herentals · balance sheet 41,482 €
- Medical Robots Manufacture of medical and dental instruments and supplies Geel · balance sheet 66,424 €
Frequently asked questions about Graam
What is the revenue of Graam?
Graam files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Graam?
In Belgium, the VAT number is the company number prefixed with BE: BE0781463276 for Graam, if the company is VAT-registered. Its company number (CBE) is 0781.463.276.
Where is the registered office of Graam?
According to the CBE register, the registered office of Graam is in 1050 Ixelles.
What is the equity of Graam?
At the close of the 2025 financial year, the equity of Graam amounts to 67,784 €, a solvency of 26.8% of total assets.
Who manages Graam?
The register lists 2 active mandates at Graam. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Graam
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →